Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

LG Energy Solution / Equity Capital Markets

<ul>
<li><strong>Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. </strong></li>
<li>Trading debuts across different markets have been poor. But there are some trades to be put for lock-up expiries.</li>
<li>This will be our last week of ECM weekly notes for the year. Our weekly notes will be back in January when things start to pick up again.</li>
</ul>


Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs. 
Trading debuts across different markets have been poor. But there are some trades to be put for lock-up expiries.
This will be our last week of ECM weekly notes for the year. Our weekly notes will be back in January when things start to pick up again.


ECM Weekly (19th December 2021) - LG Energy, Hyundai Engineering, Chervon, Sirnaomics, JG Mag A/H

Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

<ul>
<li>Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.</li>
<li>We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.</li>
<li>We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.</li>
</ul>


Sirnaomics is a biotech with a focus on siRNA technology for oncology and fibrosis diseases, and is looking to raise up to USD 150m via a Hong Kong listing.
We look at the company's core products, including STP705 and STP707. Having looked at the company's products, we aren't convinced that they can be blockbuster drugs.
We think the company's product pipeline is too light. The company management lacks track record in siRNA development and investors are mostly domestic individuals and funds.


Sirnaomics Pre-IPO: Not a Convincing siRNA Pipeline

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<p>In recent years, with the successful development and large-scale use of mRNA COVID-19 vaccine worldwide, RNA-based therapeutics have caught the attention of the public. Meanwhile, with the advancement of target discovery technology and the maturation of chemical modification and delivery technology, RNA-based therapeutics are expected to become a major treatment option in the future. On July 15, 2021, <a href="https://www.smartkarma.com/entities/sirnaomics-inc" target="_blank" data-smartkarma-citation="entities:33804:1" rel="noopener">Sirnaomics (1400833D US)</a>, the first and only clinical-stage RNA therapeutics biopharmaceutical company, formally submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the delivery platforms, the pipeline and the concerns of the Company.</p>

In recent years, with the successful development and large-scale use of mRNA COVID-19 vaccine worldwide, RNA-based therapeutics have caught the attention of the public. Meanwhile, with the advancement of target discovery technology and the maturation of chemical modification and delivery technology, RNA-based therapeutics are expected to become a major treatment option in the future. On July 15, 2021, Sirnaomics (1400833D US), the first and only clinical-stage RNA therapeutics biopharmaceutical company, formally submitted its prospectus to the HKEX for listing on the main board. This insight mainly analyzed the industry characteristics, the delivery platforms, the pipeline and the concerns of the Company.

Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended

United States

Sirnaomics Ltd. operates as a clinical-stage RNA therapeutics biopharmaceutical company. The Company's products includes oncology, fibrosis-related diseases as well as antiviral and cardiometabolic diseases. Sirnaomics conducts businesses in USA and China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sirnaomics (2257 HK)

ECM Weekly (19th December 2021) - LG Energy, Hyundai Engineering, Chervon, Sirnaomics, JG Mag A/H

Aequitas Research puts out a weekly update on the deals that have been covered by the team recently along with updates for upcoming IPOs.

Sumeet Singh

Sirnaomics Pre-IPO: Not a Convincing siRNA Pipeline

Sirnaomics, a US and China based biotech company focusing on the siRNA, is looking for a listing in Hong Kong. We look at the siRNA technology and...

Ke Yan, CFA, FRM

Pre-IPO Sirnaomics Ltd. - Cautious Optimism Is Still Recommended

This article mainly analyzed Sirnaomics in terms of the industry characteristics, the delivery platforms, the pipeline and the concerns of the...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)